NEW YORK, NY--(Marketwire - May 16, 2012) - Immunovative, Inc. ("IMUN") (OTCBB: IMUN) today announced that Dr. Michael Har-Noy, the Founder and Chief Executive Officer of Immunovative Therapies, Ltd., has been invited to make a presentation at the 5th World Cancer Congress to be held on May 18-20, 2012 in Beijing, China. Dr. Har-Noy will speak on Tumor Immunology and Immunotherapy, based upon his expertise and worldwide reputation in Cancer Immunology.
Dr. Michael Har-Noy stated: "I am pleased to have the opportunity to present our new generation of immunotherapy to an international audience of cancer professionals. I am looking forward to meeting colleagues in the Far East and establishing new relationships for collaboration at the conference."
The aim of the Congress is to provide a high quality program designed to attract delegates from all cancer research disciplines & anti-cancer medicine development, and encourage these researchers to interact and in some cases forge new collaborations. More than 500 invited cancer specialists from a wide range of disciplines will participate in the Scientific Program and their presentations will provide delegates with information on the latest developments in basic science and clinical treatment.
About Immunovative Therapies, Ltd.: Immunovative Therapies, Ltd. ("ITL") is an Israeli biopharmaceutical company that was founded in May 2004 with financial support from the Israel Office of the Chief Scientist. ITL is a graduate of the Misgav Venture Accelerator, a member of the world-renowned Israel technological incubator program. ITL was the Misgav Venture Accelerator's candidate for the prize for the outstanding incubator project of 2006, awarded by the Office of the Chief Scientist. ITL specializes in the development of novel immunotherapy drug products that incorporate living immune cells as the active ingredients for treatment of cancer and infectious disease. ITL is developing a new class of immunotherapy drugs designed to harness the power of the immune system to treat cancer. ITL has two experimental immunotherapy products for the treatment of cancer in clinical development: AlloStim™ and AlloVax™ covered by Immunovative's 10 U.S. patents granted, 15 U.S. patents pending and 26 corresponding applications pending internationally. Please visit ITL's website at: www.immunovative.co.il
About Immunovative, Inc.: On December 15, 2011, Immunovative, Inc. ("IMUN") (then known as Novo Energies Corp.) signed an exclusive License Agreement (the "License Agreement") with Immunovative Therapies, Ltd ("ITL"). Under the terms of the License Agreement, IMUN has been granted an exclusive, worldwide license to commercialize any products covered under ITL's current issued and pending patent application portfolio, as well as the rights to any future patent applications, including improvements or modifications to the existing applications and any corresponding improvements or new versions of the existing products including.
DISCLAIMER Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on IMUN's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which IMUN has little or no control. Such forward-looking statements are made only as of the date of this release, and IMUN assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by IMUN with the Securities and Exchange Commission.